Drug Delivery Systems Immune Response Vaccination 
STAT News
NOVEMBER 3, 2022
… A Delaware federal court refused to throw out patent infringement claims brought by Arbutus Biopharma and Genevant Sciences against Moderna over its sale of Covid-19 vaccine doses to the U.S. Genevant and Arbutus sued Moderna in February, seeking royalties from Moderna’s sale of its Covid-19 vaccine.
XTalks
NOVEMBER 3, 2021
In this episode, Ayesha discusses the FDA’s authorization of Pfizer/BioNTech’s COVID-19 vaccine for children between five and 11 years of age. The editorial team discussed the positive trial data, the importance of vaccinating kids amid rising infections among younger children, as well as vaccine hesitancy among parents.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
FEBRUARY 18, 2022
Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. In addition, myeloid cell targeting therapies are being investigated for their potential in the treatment of various inflammatory disorders. Web: [link].
Roots Analysis
MAY 21, 2024
Vaccines: LNPs have been increasingly used in vaccine development due to their ability to efficiently encapsulate and deliver antigens, that elicit a potent immune response ( through antibody production and T-cells activation ). Further, they have been extensively utilized in the development of mRNA vaccines for COVID-19.
Pharmaceutical Technology
APRIL 24, 2023
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.
Expert insights. Personalized for you.
97 
Let's personalize your content